Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A two-component synthetic peptide preparation pairing a tetrasubstituted 29-residue GRF(1-29) analog with a five-residue amidated pentapeptide, used in comparative preclinical research.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Peptide blend
Molecular formula
C152H252N44O42
Molecular weight
~3,368 g/mol
CAS number
863288-34-0
Sequence
Tetrasubstituted GRF(1-29), C-terminal amide (D-Ala at position 2)
Molecular formula
C38H49N9O5
Molecular weight
711.9 g/mol
CAS number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Combines two structurally distinct synthetic peptides. CJC-1295 / Mod GRF 1-29 is a 29-residue analog corresponding to the GRF(1-29) sequence with four substitutions (a D-amino-acid residue at position 2 plus substitutions at positions 8, 15, and 27) that confer protease resistance; in its long-circulating form a maleimido-linked side chain forms a covalent bond with serum albumin, extending plasma residence. Ipamorelin is a five-residue C-terminally amidated pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) whose non-proteinogenic residues confer metabolic stability. The two molecules engage separate G-protein-coupled receptor classes (class B and class A GPCRs) as structural binding contexts, so no single molecular target describes the pair.
Lyophilized
20°C
typically stable 24-36 months desiccated and protected from light.
Avoid freeze-thaw; aliquot; protect from light and moisture.
Reviews
Bowers CY. (1998). Compr Physiol
Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. (2025). Rev Endocr Metab Disord
Laviano A, Molfino A, Rianda S, Rossi Fanelli F. (2012). Curr Pharm Des
Reviews
Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. (2000). Recent Prog Horm Res
Ghigo E, Arvat E, Muccioli G, Camanni F. (1997). Eur J Endocrinol
Clinical
Beck DE, Sweeney WB, McCarter MD, et al. (2014). Int J Colorectal Dis
Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. (2006). J Clin Endocrinol Metab
Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. (1999). Pharm Res
Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. (1998). J Clin Endocrinol Metab
Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. (1990). J Clin Endocrinol Metab
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. (2009). Growth Horm IGF Res
Primary research
Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. (2006). Am J Physiol Endocrinol Metab
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. (2005). Endocrinology
Svensson J, Lall S, Dickson SL, Bengtsson BÅ, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. (2000). J Endocrinol
Johansen PB, Nowak J, Skjærbæk C, Flyvbjerg A, Andreassen TT, Wilken M, Ørskov H. (1999). Growth Horm IGF Res
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. (1998). Eur J Endocrinol
Renner U, Brockmeier S, Strasburger CJ, et al. (1994). J Clin Endocrinol Metab
Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. (2002). Histol Histopathol
Andersen NB, Malmlöf K, Johansen PB, et al. (2001). Growth Horm IGF Res
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| CJC-1295 / Ipamorelin BlendThis page | Peptide blend | — | — |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods